Replies to post #107688 on Biotech Values

[jbog]

biopearl,

I've noticed that recently some of the analysts have been realizing that Teva's t-enox delay has to do with something other than that they filed a reply one month after Momenta.

Teva may never say anything unless they were to get a direct no from the fda, and if the fda hasn't said no to Amphastar yet I can't see it declining Teva.

Time will tell.

[alertmeipp]

they won't, I suggest we should take advantage of that.
NVS knows - they maybe willing to pay a high price tag for MNTA because of it.